All In Biotech

Drug Trial Radar · NCT05061719

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

812

Actual

Start

Oct 8, 2021

Primary completion

Oct 14, 2024

Study completion Oct 23, 2024

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Sep 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.

Conditions

  • Major Depressive Disorder

Interventions

  • LumateperoneDrug

    Lumateperone 42 mg capsules administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number and Percentage of Patients Reporting Treatment Emergent Adverse EventsTime frame: 26 weeks

Locations

109 sites in 11 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Phoenix, Arizona

  • Clinical Site

    Bentonville, Arkansas

  • Clinical Site

    Little Rock, Arkansas

  • Clinical Site

    Rogers, Arkansas

  • Clinical Site

    Culver City, California

  • Clinical Site

    Glendale, California

  • Clinical Site

    Newport Beach, California

  • Clinical Site

    Oceanside, California

  • Clinical Site

    Redlands, California

  • Clinical Site

    Riverside, California

  • Clinical Site

    San Diego, California

  • Clinical Site

    Sherman Oaks, California

  • Clinical Site

    Temecula, California

  • Clinical Site

    Upland, California

  • Clinical Site

    Fort Lauderdale, Florida

  • Clinical Site

    Jacksonville, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Palm Bay, Florida

  • Clinical Site

    West Palm Beach, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Decatur, Georgia

  • Clinical Site

    Joliet, Illinois

  • Clinical Site

    Overland Park, Kansas

  • Clinical Site

    Gaithersburg, Maryland

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Flowood, Mississippi

  • Clinical Site

    Saint Charles, Missouri

  • Clinical Site

    Berlin, New Jersey

  • Clinical Site

    Toms River, New Jersey

  • Clinical Site

    Brooklyn, New York

  • Clinical Site

    Cedarhurst, New York

  • Clinical Site

    Mount Kisco, New York

  • Clinical Site

    Charlotte, North Carolina

  • Clinical Site

    Allentown, Pennsylvania

  • Clinical Site

    Media, Pennsylvania

  • Clinical Site

    Plymouth Meeting, Pennsylvania

  • Clinical Site

    Austin, Texas

  • Clinical Site

    Bellevue, Washington

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.